55
Participants
Start Date
April 18, 2017
Primary Completion Date
September 22, 2020
Study Completion Date
July 5, 2022
Vedolizumab
Vedolizumab intravenous infusion.
Adalimumab
Adalimumab injection for subcutaneous use.
Methotrexate
Methotrexate oral tablets.
Icahn School of Medicine at Mt. Sinai, New York
Carolinas HealthCare System Digestive Health, Charlotte
Digestive Health Partners, PS, Asheville
Gastro Florida, Clearwater
Digestive Health Specialists of the Southeast, Dothan
University of Mississippi Medical Center, Jackson
The Ohio State University Wexner Medical Center, Columbus
Center for Digestive Health, Troy
Huron Gastroenterology Associates, Ypsilanti
Minnesota Gastroenterology, PA - Plymouth, Plymouth
Northshore University HealthSystem, Evanston
University of Kansas Medical Center, Kansas City
Cotton O'Neil Clinical Research, Topeka
Texas Digestive Disease Consultants Baton Rouge, Baton Rouge
Louisana Research Center, LLC, Shreveport
Digestive Disease Specialists, Inc., Oklahoma City
Options Health Research, LLC, Tulsa
Tyler Research Institute, LLC, Tyler
Texas Digestive Disease Consultants Southlake, Southlake
Baylor College of Medicine, Houston
Texas Digestive Disease Consultants, Webster, Webster
Pinnacle Clinical Research, San Antonio
Grand Teton Research Group, PLLC, Idaho Falls
University of Utah Health Sciences Center, Salt Lake City
Las Vegas Medical Research, Las Vegas
Digestive Health Specialists, Tacoma
Atlanta Gastroenterology Associates, Atlanta
Covenant Health, Edmonton
PerCuro Clinical Research Ltd, Victoria
LHSC - Victoria Hospital, London
Toronto Digestive Disease Associates Inc, Vaughan
CIUSSS de I'Estrie-CHUS, Sherbrooke
Lead Sponsor
Takeda
INDUSTRY